Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Mayo Clin Proc. 2020 Jan;95(1):124–133. doi: 10.1016/j.mayocp.2019.07.008

Table 1.

Baseline Characteristics of all DM and non-DM Patients

Variable Non-DM DM P-value
(N=232) (N=116)
Age at Exam (years) 66.6± 9.4 66.6± 9.4 .98
Gender, n (%) 98 (42%) 49 (42%) --
BMI of Patient 28.8± 5.2 30.8± 5.5 .001
BMI>30, n (%) 84 (36%) 58 (50%) .01
Waist>102M, 88F, n(%) 92 (40%) 57 (49%) .09
Metabolic Syndrome, n (%) 54 (23%) 62 (54%) .001
Verified Hypertension, n(%) 118 (51%) 62 (53%) .65
CAD (%) 58 (25%) 38 (33%) .13
HF (n%) 1 (0%) 4 (3%) .03
MI n,(%) 20 (9%) 17 (15%) .09
Atrial Fib/Flutter n,(%) 9 (4%) 11 (9%) .03
Stroke n,(%) 5 (2%) 2 (2%) .79
Beta Blocker, n(%) 59(27%) 33 (29%) .63
Calcium Channel Blocker, n(%) 35 (16%) 19 (17%) .82
ACE Inhibitor, n(%) 23 (10%) 36 (32%) <.001
Antilipemic Therapy, n(%) 66 (30%) 40 (35%) .30
Total Cholesterol (mg/dL) 199.9± 36.9 138.2± 20.4 .04
LDL Cholesterol (mg/dL) 125.9± 32.8 115.5± 32 .005
Triglycerides (mg/dL) 146.4± 79.6 183.2± 121.8 <.001
HDL (mg/dL) <40M, <50F, n(%) 122 (53%) 83 (72%) <.001
NT-proBNP (pg/mL), median (Q1, Q3) 76.9 (32.3, 153.6) 81.9 (31.8, 182.3) .69
Aldosterone (pg/ml), median (Q1, Q3) 5.6 (3, 8.7) 4.9 (2.5, 8.6) .52
Insulin (uU/mL), median (Q1, Q3) 5.8 (4.1, 8.7) 8.5 (5.1, 15.7) <.001
Creatinine (mg/dL), median (Q1, Q3) 0.9 (0.8, 1.0) 0.9 (0.8, 1.0) .63
SBP (mmHg) 136.8± 22.2 138.2±20.4 .56
DBP (mmHg) 74.7± 10.6 72.3±8.5 .04
Serum Glucose (mg/dL), median (Q1, Q3) 95 (90, 102) 130 (107,167) <.001
a

ACE angiotensin-converting enzyme, BMI body mass index, CAD coronary artery disease, HF heart failure, DBP diastolic blood pressure, MI myocardial infarction, HDL high-density lipoprotein, LDL low-density lipoprotein, NT-proBNP n-terminal pro hormone b-type natriuretic peptide, SBP systolic blood pressure

b

dL deciliter, mg milligram, mmHg millimeters of mercury, Pg picogram, uU international units